Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis
Sponsor: ICM Biotech Australia Pty Ltd.
Summary
The purpose of this study is to determine the safety, tolerability, and activity of ICM-203, a recombinant adeno-associated viral (AAV) vector that expresses a therapeutic gene that promotes cartilage formation, reduces joint inflammation and pain, as well as improves joint physical function, by injecting escalating doses of ICM-203 or matching placebo into the knee of subjects with mild to moderate knee osteoarthritis (OA).
Official title: A Phase 1/2a, Double-Blind, Placebo-Controlled Single Dose Escalation Study of Intra-Articular ICM 203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2022-03-17
Completion Date
2026-12
Last Updated
2025-05-01
Healthy Volunteers
No
Conditions
Interventions
ICM-203
Intra-articular injection
Placebo
Intra-articular injection
Locations (2)
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Barwon Health
Geelong, Victoria, Australia